

<p>What's in this issue?</p>	<ol style="list-style-type: none"> 1. Ruruku – Latest News and Updates from Te Whatu Ora and Te Aka Whai Ora September 21 2023 2. Revised Model of Care for COVID-19 from October 1 2023 3. COVID-19 Access Criteria 4. Health & Disability Commissioner: New 'Your Rights' Video and Online Learning Modules 5. Pharmaceutical Schedule Dispatch 6. Therapeutic Products Update September 2023 7. Register for OA Summit Dunedin November 2-4 2023 8. National Antimicrobial Guidelines – Introductory Letter 9. Supply Issue with Teva Brand Methylphenidate ER 10. Supply Updates for Pharmacists September 22 2023 11. Updates for Pharmacists in General Practice - <i>No update received this week</i> 12. Top Weekend Viewing
<p>Ruruku – Latest News and Updates from Te Whatu Ora and Te Aka Whai Ora September 21 2023 View online</p>	<ul style="list-style-type: none"> • You can view Ruruku online covering the following: <ul style="list-style-type: none"> ○ Message from Chief Executives ○ Stakeholder virtual hui recordings ○ Settlement reached with midwives and maternity care assistants ○ Mental health awareness week 18-24 September ○ Whakatāne Hospital celebrates 100 years ○ New cervical screening test will be a 'game changer' in reducing cervical cancer rates ○ Growing our Māori and Pacific workforce ○ Kaupapa Māori suicide prevention services investment ○ New appointment Interim National Chief Nursing Officer - Emma Hickson ○ Applications open for the 2024/25 Harkness Fellowships
<p>Revised Model of Care for COVID-19 from October 1 2023 <i>See attached email</i></p>	<ul style="list-style-type: none"> • See attached update on the revised Model of Care for COVID-19 from October 1 2023 and update on pulse oximeters. This covers: <ul style="list-style-type: none"> ○ Collateral LINK TO PUBLIC COLLATERAL ○ Option to order printed versions of collateral ○ Narrative for websites on the transition of COVID-19 care ○ News item ○ Testing • Pulse oximeters: <ul style="list-style-type: none"> ○ The funded provision of pulse oximetry to Primary Care from 1 October 2023 will end in line with planned funding changes for COVID-19. ○ Pulse oximeters were introduced during an international surge in the Delta variant of COVID-19 in 2019. However, there is little evidence to support their continued use in measuring deterioration with the Omicron variant, helped in part with the innovations of vaccination and antiviral therapies. ○ There are a number of pulse oximeters for order should you like to use them in your practice or for specific patients. These can be ordered through your standard ordering channels until stock is exhausted.

<p>COVID-19 Access Criteria</p>	<ul style="list-style-type: none"> Pharmac has made changes to the access criteria for nirmatrelvir with ritonavir (Paxlovid), molnupiravir (Lageviro) and remdesivir (Veklury) for the treatment of COVID-19. These changes mean that disabled people at a high risk of severe illness from COVID-19 and people with frailty or vulnerability due to one or more severe health conditions will have access to COVID-19 antiviral treatments. For more information, please follow this link.
<p>Health & Disability Commissioner: New 'Your Rights' Video and Online Learning Modules</p>	<ul style="list-style-type: none"> When you use a health or disability service in Aotearoa New Zealand, you have the protection of the Code of Rights. With this in mind, HDC has produced an animated video to explain your rights so you can ask questions, get support and make sure your voices are heard have launched their consumer video. You can find the video in te reo Māori and English at www.hdc.org.nz/your-rights/videos. There are also resources for providers. The three free online modules are suitable for everyone working in the health and disability sector. They cover how the Code of Rights improves health and disability services, what you need to know about informed consent, and complaints management and early resolution and can be found at www.hdc.org.nz/education/online-learning/
<p>Pharmaceutical Schedule Dispatch</p>	<ul style="list-style-type: none"> This is a summary of the changes to be announced in next month's Community Schedule (Section B) and Hospital Schedule (Section H). <ul style="list-style-type: none"> View the changes in next month's Community Schedule View the changes in next month's Hospital Schedule The complete changes will be published in the Online Schedule and Online Hospital Medicines List (HML) around September 23 and are effective from the following month. Any questions about these listing changes or the Pharmaceutical Schedule in general, please email enquiry@pharmac.govt.nz.
<p>Therapeutic Products Update September 2023 View online</p>	<ul style="list-style-type: none"> Please see the Therapeutic Products Update for September 2023 covering: <ul style="list-style-type: none"> Programme of work Proactive release of documents Engagement Contact details
<p>Register for OA Summit Dunedin November 2-4 2023</p>	<ul style="list-style-type: none"> Osteoarthritis Aotearoa New Zealand (OA_AoNZ) are holding the 2023 OA Summit in Dunedin this year, November 2-4 https://events.otago.ac.nz/2023-oa-summit/ The first day is the Osteoarthritis Aotearoa Research Network conference, Thursday November 2 for those involved in OA research. The main OA Summit day, Friday November 3, features international and local expert keynote speakers, reports of innovative health delivery from around the motu, first-person accounts from people with OA. A special session is being offered for people with OA, presented by a range of international and local expert keynote speakers and people with OA. Thanks to the generous sponsorship of Arthritis New Zealand, people with OA can attend at no cost. Saturday morning, November 4, you are invited to attend an interactive workshop in which participants will co-design a recommended Model of Care for the management of OA in Aotearoa. This is an important initiative of OA_AoNZ that aims to strongly impact national health policy. People with OA, GPs and orthopaedic surgeons are especially invited to attend –

	<p>there is no cost and preference will be given to those who attended the OA Summit.</p>
<p>National Antimicrobial Guidelines – Introductory Letter <i>See attached letter</i></p>	<ul style="list-style-type: none"> • The attached letter is for those interested or involved with antimicrobial guidelines development. • Key contacts are: <ul style="list-style-type: none"> ○ Guideline content, and stakeholder list: antimicrobials@cdhb.health.nz ○ Guideline delivery: EamonD@adhb.govt.nz ○ Other enquiries including media: s.ritchie@auckland.ac.nz, karen.wright@auckland.ac.nz and lilyfraser@gmail.com
<p>Supply Issue with Teva Brand Methylphenidate ER</p>	<ul style="list-style-type: none"> • Pharmac has been informed by Teva of a supply issue with its brand of methylphenidate (Teva ER methylphenidate). This affects all strengths (18, 27, 36 and 54 mg). • Solutions are currently being worked on to make it easier for people to access alternative brands (eg. Concerta or Rubifen SR). Pharmac are also working with Teva on resupply dates for Teva ER methylphenidate. • Pharmac will provide more information to the sector about how they can support patients early next week and will also publish information on the supply issue webpage as it becomes available.
<p>Supply Updates for Pharmacists September 22 2023 View online</p>	<ul style="list-style-type: none"> • See latest supply update covering: <ul style="list-style-type: none"> ○ New medicine notices ○ Updated issues ○ Resolved issues ○ Recent decisions ○ Open consultations ○ Monthly updates
<p>Updates for Pharmacists in General Practice September 15 2023 <i>(No update received this week – information is from last week)</i> View online</p>	<p>Supply issues: <i>Up-to-date information on supply issues can be found on the Pharmac website</i></p> <ul style="list-style-type: none"> • Methylphenidate ER 18 mg, 27 mg, and 36 mg tablets methylphenidate medicines notice • Aqueous Cream aqueous cream medicines notice • Rivastigmine Patch Rivastigmine patch medicines notice • Dulaglutide (Trulicity) 1.5 mg the dulaglutide supply issue notice • Salbutamol inhaler (Asthalin) nebuliser 1 mg per ml Salbutamol (Asthalin) nebuliser 1 mg per ml notice • Salbutamol inhaler (Respigen) Salbutamol inhaler (Respigen) notice • Nutricia foods product Nutricia medicine notice • Oestradiol (Estradot) patches oestradiol (Estradot) patches notice <p>Discontinuation:</p> <ul style="list-style-type: none"> • Colestipol hydrochloride (Colestid) and alternative treatment – more information can be found here or email enquiry@pharmac.govt.nz <p>Resolved issues:</p> <ul style="list-style-type: none"> • Laxsol (Docusate sodium with sennosides) • Amoxicillin with clavulanic acid 50 / 12.5 mg per ml (grans for oral liquid) • Permethrin 5% lotion (A-Scabies) • Diclofenac (Voltaren Optha) eye drops <p>Recent decisions:</p> <ul style="list-style-type: none"> • Decision to widen access to medicines for severe haemophilia A and multiple sclerosis <p>Open consultations:</p>

	<ul style="list-style-type: none"> • Call for funding applications for vaccines providing protection against COVID-19 <p><i>Increase in the number of supply issues:</i></p> <ul style="list-style-type: none"> • There has been an increase in the number of medicines supply issues that suppliers are faced with. In most cases, COVID-19 has been the cause of this impact on medicine supply chains. COVID-19 is likely to continue to have global impacts on medicine manufacturing and supply chains for some time to come. For up-to-date information about supply issues please check the Pharmac website. <p><i>Expressions of Interest for Pharmac’s Advisory Committees:</i></p> <ul style="list-style-type: none"> • If you are interested in being involved in Pharmac’s clinical advice network, see Pharmac website, please send an email to advisorycommittees@pharmac.govt.nz outlining your specific clinical area(s) of interest.
<p>Top Weekend Viewing</p>	<ul style="list-style-type: none"> • As it’s Mental Health Awareness Week, and with many people in our society struggling with mental health, these inspiring stories on TVNZ+ are well worth watching. <ul style="list-style-type: none"> ○ Behind the Jersey – Voices of Hope shines a spotlight on mental health in the world of sports; uncovering the challenges that exist for sportspeople 'behind the jersey'. ○ You, Me and Anxiety – Local actress Robyn Malcolm shares her personal experiences with anxiety and panic attacks in a frank, funny and illuminating documentary about this debilitating and common human condition. ○ I Am Tui Taurua: I Am A Mental Health Warrior – Tui spent more than two decades in and out of psychiatric hospitals because of the way the western lens viewed the voices she was hearing in her head.